Brief: Pledpharma and Solasia enter license agreement on Pledox in Asia

Egetis Therapeutics AB (publ)

20/11/2017 06:30

Nov 20 (Reuters) - PLEDPHARMA AB (PUBL)  PLED.ST  
    * PLEDPHARMA AND SOLASIA ENTER LICENSE AGREEMENT TO DEVELOP 
AND 
COMMERCIALIZE PLEDOX IN ASIA  
    * PLEDPHARMA AB (PUBL) - SOLASIA WILL PAY UPFRONT, 
DEVELOPMENT, 
REGULATORY AND SALES MILESTONES OF UP TO ABOUT USD 83 MILLION 
    * PLEDPHARMA AB (PUBL) - SOLASIA WILL PAY INDUSTRY STANDARD 
ROYALTY RATES ON SALES 
    * PLEDPHARMA AB (PUBL) - WILL ALSO FULLY FINANCE AN 
EXPANSION OF 
PHASE III PROGRAM FOR PLEDOX 
    * TOTAL VALUE OF UPFRONT AND MILESTONE PAYMENTS IS UP TO 
JPY 9.3 
BILLION 
    * PHASE III STUDIES ANTICIPATED TO BE INITIATED END OF 2017 
WITH 
TOP LINE RESULTS EXPECTED IN 2020 
 
Source text for Eikon:  ID:nSSN7dNm  
Further company coverage:  PLED.ST  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))